Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Complement receptor C3aR1 controls neutrophil mobilization following spinal cord injury through physiological antagonism of CXCR2
Faith H. Brennan, Trisha Jogia, Ellen R. Gillespie, Linda V. Blomster, Xaria X. Li, Bianca Nowlan, Gail M. Williams, Esther Jacobson, Geoff W. Osborne, Frederic A. Meunier, Stephen M. Taylor, Kate E. Campbell, Kelli P.A. MacDonald, Jean-Pierre Levesque, Trent M. Woodruff, Marc J. Ruitenberg
Faith H. Brennan, Trisha Jogia, Ellen R. Gillespie, Linda V. Blomster, Xaria X. Li, Bianca Nowlan, Gail M. Williams, Esther Jacobson, Geoff W. Osborne, Frederic A. Meunier, Stephen M. Taylor, Kate E. Campbell, Kelli P.A. MacDonald, Jean-Pierre Levesque, Trent M. Woodruff, Marc J. Ruitenberg
View: Text | PDF
Research Article Inflammation Neuroscience

Complement receptor C3aR1 controls neutrophil mobilization following spinal cord injury through physiological antagonism of CXCR2

  • Text
  • PDF
Abstract

Traumatic spinal cord injury (SCI) triggers an acute-phase response that leads to systemic inflammation and rapid mobilization of bone marrow (BM) neutrophils into the blood. These mobilized neutrophils then accumulate in visceral organs and the injured spinal cord where they cause inflammatory tissue damage. The receptor for complement activation product 3a, C3aR1, has been implicated in negatively regulating the BM neutrophil response to tissue injury. However, the mechanism via which C3aR1 controls BM neutrophil mobilization, and also its influence over SCI outcomes, are unknown. Here, we show that the C3a/C3aR1 axis exerts neuroprotection in SCI by acting as a physiological antagonist against neutrophil chemotactic signals. We show that C3aR1 engages phosphatase and tensin homolog (PTEN), a negative regulator of the phosphatidylinositol 3-kinase (PI3K)/AKT pathway, to restrain C-X-C chemokine receptor type 2–driven BM neutrophil mobilization following trauma. These findings are of direct clinical significance as lower circulating neutrophil numbers at presentation were identified as a marker for improved recovery in human SCI. Our work thus identifies C3aR1 and its downstream intermediary, PTEN, as therapeutic targets to broadly inhibit neutrophil mobilization/recruitment following tissue injury and reduce inflammatory pathology.

Authors

Faith H. Brennan, Trisha Jogia, Ellen R. Gillespie, Linda V. Blomster, Xaria X. Li, Bianca Nowlan, Gail M. Williams, Esther Jacobson, Geoff W. Osborne, Frederic A. Meunier, Stephen M. Taylor, Kate E. Campbell, Kelli P.A. MacDonald, Jean-Pierre Levesque, Trent M. Woodruff, Marc J. Ruitenberg

×

Figure 1

C3a production after SCI and expression of its receptor, C3aR1, in the damaged neural parenchyma.

Options: View larger image (or click on image) Download as PowerPoint
C3a production after SCI and expression of its receptor, C3aR1, in the d...
(A) C3a levels in the spinal cord rapidly increased in response to injury, peaking at 1 day after SCI. (B) Circulating C3a levels were also significantly increased within 2 hours of SCI, and they remained well above those observed in sham-operated control mice for up to 1 day after injury. Data points are mean ± SEM (n = 4–5 per genotype per time point). **P < 0.01, ***P < 0.001; ****P < 0.0001 by 2-way ANOVA with Bonferroni’s post hoc test (SCI vs. time-matched sham-operated control). (C–F) Representative images of C3aR1 (or Ly6B.2 in E; red) staining during the acute (1 day) and more chronic (35 days) phase of SCI. Merged images of costains (green and/or blue) with nuclear dye (cyan), and Imaris surface reconstructions for colocalization analysis are shown on the right (r2 value = square of Pearson’s correlation for colocalization). C3aR1 was expressed on both Ly6B.2+ (C) and CD11b+ (D) cells. (E) Ly6B.2+ cells in the injured spinal cord of Cx3cr1gfp/+ mice do not express GFP, indicating that they are infiltrating neutrophils. (F) Representative image showing C3aR1 staining in WT spinal cord at 35 days after injury. C3aR1 colocalized to amoeboid-shaped Iba1+ microglia/macrophages (blue) and fibrous GFAP+ astrocytes (green); other C3aR1-expressing cells can also be seen (arrowheads). (G) Confirmation of C3aR1 staining and antibody specificity on lesioned C3ar1–/– spinal cord tissue. (H) Higher-power confocal image of an infiltrating Ly6B.2+ neutrophil (green) coexpressing C3aR (red) in the spinal cord at 35 days after injury. Images are representative of 3 mice per time point and condition. Scale bars: 14 μm (C), 20 μm (G), and 4 μm (H).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts